TSE:MDNA Medicenna Therapeutics (MDNA) Stock Price, News & Analysis C$0.88 +0.01 (+1.15%) As of 09:45 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesBuy This Stock About Medicenna Therapeutics Stock (TSE:MDNA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Medicenna Therapeutics alerts:Sign Up Key Stats Today's RangeC$0.88▼C$0.8850-Day RangeC$0.83▼C$1.2252-Week RangeC$0.78▼C$2.63Volume735 shsAverage Volume47,380 shsMarket CapitalizationC$65.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients. Read More Receive MDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MDNA Stock News HeadlinesMedicenna Therapeutics Corp.: Medicenna Therapeutics Reports Fiscal Year 2025 Financial Results and Operational HighlightsJune 26, 2025 | finanznachrichten.deMedicenna to Present at Jones Healthcare and Technology Innovation ConferenceApril 1, 2025 | markets.businessinsider.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.July 3 at 2:00 AM | American Alternative (Ad)Medicenna Therapeutics reports clinical data from ABILITY-1 study of MDNA11February 25, 2025 | markets.businessinsider.comMedicenna Reports Third Quarter Fiscal 2025 Financial and Operational Results and Provides Anticipated MilestonesFebruary 13, 2025 | uk.finance.yahoo.comMedicenna’s MDNA11 Shows Promising Cancer Treatment ResultsDecember 6, 2024 | markets.businessinsider.comMedicenna Therapeutics Corp.: Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate UpdateNovember 15, 2024 | finanznachrichten.deMedicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate UpdateNovember 15, 2024 | finance.yahoo.comSee More Headlines MDNA Stock Analysis - Frequently Asked Questions How have MDNA shares performed this year? Medicenna Therapeutics' stock was trading at C$1.65 on January 1st, 2025. Since then, MDNA shares have decreased by 46.7% and is now trading at C$0.88. View the best growth stocks for 2025 here. How do I buy shares of Medicenna Therapeutics? Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Medicenna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medicenna Therapeutics investors own include Manulife Financial (MFC), Gilead Sciences (GILD), OPKO Health (OPK), Air Canada (AC), Athersys (ATHX), Birchcliff Energy (BIR) and Canadian Natural Resources (CNQ). Industry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolTSE:MDNA CIKN/A Webwww.medicenna.com Phone+1-403-6807898FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-C$25.98 million Net Margins-533,640.00% Pretax MarginN/A Return on Equity-159.88% Return on Assets-32.80% Debt Debt-to-Equity Ratio0.88 Current Ratio11.40 Quick Ratio4.65 Sales & Book Value Annual SalesC$4.87 thousand Price / Sales13,523.42 Cash FlowC$0.77 per share Price / Cash Flow1.15 Book ValueC$0.26 per share Price / Book3.37Miscellaneous Outstanding Shares74,815,113Free FloatN/AMarket CapC$65.84 million OptionableNot Optionable Beta1.21 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (TSE:MDNA) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredThe Pentagon just made a National Security move...This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.......Stansberry Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredA grave, grave error.President Donald Trump made headlines last month with a staggering claim. He stated that since taking offic...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicenna Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicenna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.